The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2020

Filed:

Jul. 12, 2018
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Jessica R. Kirshner, New York, NY (US);

Douglas MacDonald, New York, NY (US);

Gavin Thurston, Briarcliff Manor, NY (US);

Joel H. Martin, Putnam Valley, NY (US);

Frank Delfino, Poughquag, NY (US);

Thomas Nittoli, Pearl River, NY (US);

Marcus Kelly, New York, NY (US);

Assignee:

REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); C07K 16/30 (2013.01); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.


Find Patent Forward Citations

Loading…